H.R. 8333 · 118th Congress (2023–2025)
BIOSECURE Act
This bill prohibits entities that receive federal funds from using biotechnology that is from a company associated with a foreign adversary.
Specifically, federal agencies and recipients of federal funds (e.g., grantees) may not procure or use any biotechnology equipment or service that is from a biotechnology company of concern and may not contract with any entities that do so. A biotechnology company of concern is an entity that is under the control of a foreign adversary and that poses a risk to national security based on its research or multiomic data collection (e.g., collection of genomic information).
The Office of Management and Budget (OMB) must, in coordination with the Department of Defense (DOD) and other specified agencies, develop a list of prohibited companies; the list must include five particular companies, as specified in the bill. OMB and DOD may approve waivers of these restrictions on an as-needed basis, which are valid for up to one year and may be extended once for an additional 180 days.
In addition, the Office of the Director of National Intelligence must report on the national security risks posed by (1) multiomic data collection by foreign adversaries in connection with biotechnology equipment or services, and (2) biotechnology companies that have such data.
Show official title
To prohibit contracting with certain biotechnology providers, and for other purposes.
Expired in Senate committee
Derived from the legislative history, not an official disposition.
Latest actionReferred to committee
This bill’s path
122 days after it was introduced
This is H.R. 8333’s recorded path, not a universal congressional workflow.
How bills become lawAll actionsIntroduced4 months
Passed House
Passed Senate
Sent to President
Signed into law
Expired
- Sponsor
- Rep. Brad R. Wenstrup (R-OH-2)
- Cosponsors
14 cosponsors
7 original · 7 later
7 R · 7 D
- Rep. Donald G. Davis (D-NC-1)· Original · May 10, 2024
- Rep. Neal P. Dunn (R-FL-2)· Original · May 10, 2024
- Rep. Anna G. Eshoo (D-CA-16)· Original · May 10, 2024
- Rep. Raja Krishnamoorthi (D-IL-8)· Original · May 10, 2024
- Rep. John R. Moolenaar (R-MI-2)· Original · May 10, 2024
- Rep. Seth Moulton (D-MA-6)· Original · May 10, 2024
- Rep. Elise M. Stefanik (R-NY-21)· Original · May 10, 2024
- Rep. Ashley Hinson (R-IA-2)· Later · May 14, 2024
- Rep. Elissa Slotkin (D-MI-7)· Later · May 14, 2024
- Rep. Stephanie I. Bice (R-OK-5)· Later · May 21, 2024
- Rep. Josh Gottheimer (D-NJ-5)· Later · May 21, 2024
- Rep. Darin LaHood (R-IL-16)· Later · Jul 8, 2024
- Rep. Thomas R. Suozzi (D-NY-3)· Later · Jul 8, 2024
- Rep. Mark E. Green (R-TN-7)· Later · Sep 9, 2024
- Policy area
- Health
- Subjects
- Asia
- China
- Congressional oversight
- Diplomacy, foreign officials, Americans abroad
- Foreign and international corporations
- Government employee pay, benefits, personnel management
- Government information and archives
- Government lending and loan guarantees
3 more
- Government studies and investigations
- Health technology, devices, supplies
- Public contracts and procurement
On this page
Timeline
i
In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.
Introduced in House
Document: Introduced in House
Sources
- Congress.gov actionIntro-H
- Library of Congress
▸ 3 committee actions · May 10, 2024 – May 15, 2024
Referred to committee
Referred to the Committee on Oversight and Accountability, and in addition to the Committee on Intelligence (Permanent Select), for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Sources
- Congress.gov action
- House floor actions
Markup session held
Committee Consideration and Mark-up Session Held
Sources
- Congress.gov action
- House committee actions
Ordered reported
Ordered to be Reported in the Nature of a Substitute by the Yeas and Nays: 40 - 1.
Sources
- Congress.gov action
- House committee actions
Passed House
Congressional Record H5051–H5052
On motion to suspend the rules and pass the bill, as amended Agreed to by the Yeas and Nays: (2/3 required): 306 - 81 (Roll no. 402).
The House passed the bill as amended.
Document: Engrossed in House
Sources
- Congress.gov action
- House Roll Call Vote 402
- House floor actions
- Latest
Referred to committee
Received in the Senate and Read twice and referred to the Committee on Homeland Security and Governmental Affairs.
Sources
- Congress.gov action
- Senate
Expired
Passed House → Referred to Senate Homeland Security and Governmental Affairs → No further action before the 118th Congress ended.
Roll-call votes
Committees
May 15, 2024 · Markup
Floor record
i
Explicit consideration evidence: the measure’s bill-status citation matched a GovInfo title, headline, or first paragraph. Incidental mentions are not listed.
Sep 9, 2024 · House · Considered under suspension of the rulesCongressional Record H5051–H5058
Biosecure Act
Sep 9, 2024 · House · Considered as unfinished businessCongressional Record H5081–H5082
Biosecure Act
Text & titles
i
Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.
Titles (2)
BIOSECURE Act
Short title, Display title · Referred in Senate, Engrossed in House, Introduced in House
To prohibit contracting with certain biotechnology providers, and for other purposes.
Official title · Introduced in House